RU2644258C2 - Способы и материалы для лечения болезни помпе - Google Patents

Способы и материалы для лечения болезни помпе Download PDF

Info

Publication number
RU2644258C2
RU2644258C2 RU2014139953A RU2014139953A RU2644258C2 RU 2644258 C2 RU2644258 C2 RU 2644258C2 RU 2014139953 A RU2014139953 A RU 2014139953A RU 2014139953 A RU2014139953 A RU 2014139953A RU 2644258 C2 RU2644258 C2 RU 2644258C2
Authority
RU
Russia
Prior art keywords
amino acid
polypeptide
mannose
seq
gaa
Prior art date
Application number
RU2014139953A
Other languages
English (en)
Russian (ru)
Other versions
RU2014139953A (ru
Inventor
Воутер ФЕРВЕКЕН
Кейтлин Камилла Телефвор Алида Мария ПИЕНС
Ян Робет Лудо СТАУТ
Гвенда Ноэлла ПИНАЭРТ
Original Assignee
Оксирейн Юкей Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оксирейн Юкей Лимитед filed Critical Оксирейн Юкей Лимитед
Publication of RU2014139953A publication Critical patent/RU2014139953A/ru
Application granted granted Critical
Publication of RU2644258C2 publication Critical patent/RU2644258C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2014139953A 2012-03-15 2013-03-14 Способы и материалы для лечения болезни помпе RU2644258C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611485P 2012-03-15 2012-03-15
US61/611,485 2012-03-15
PCT/IB2013/000912 WO2013136189A2 (en) 2012-03-15 2013-03-14 Methods and materials for treatment of pompe's disease

Publications (2)

Publication Number Publication Date
RU2014139953A RU2014139953A (ru) 2016-05-20
RU2644258C2 true RU2644258C2 (ru) 2018-02-08

Family

ID=48626475

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014139953A RU2644258C2 (ru) 2012-03-15 2013-03-14 Способы и материалы для лечения болезни помпе

Country Status (10)

Country Link
US (2) US9249399B2 (https=)
EP (2) EP3628326B1 (https=)
JP (1) JP6194324B2 (https=)
KR (2) KR102028228B1 (https=)
CN (1) CN104379162B (https=)
AU (1) AU2013234042B2 (https=)
BR (1) BR112014022624A2 (https=)
CA (1) CA2867237C (https=)
RU (1) RU2644258C2 (https=)
WO (1) WO2013136189A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887752C (en) * 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
WO2011061629A2 (en) 2009-11-19 2011-05-26 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
CA2812872C (en) 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
EP3393501B1 (en) 2015-12-24 2023-06-07 Oxyrane UK Limited Human alpha-n-acetylgalactosaminidase polypeptide
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
TWI759291B (zh) * 2016-03-30 2022-04-01 美商阿米庫斯醫療股份有限公司 用於選擇高m6p重組蛋白之方法
CA3019354A1 (en) * 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2017239641A1 (en) * 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
SMT202300187T1 (it) 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20220125892A1 (en) 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
CA3207917A1 (en) * 2021-02-11 2022-08-18 Hung Do Recombinant human acid alpha-glucosidase and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005123986A (ru) * 2003-01-22 2007-02-27 Гликарт Биотекнолоджи АГ (CH) Конструкции слияния и их применение для получения антител с повышенными аффинностью связывания fc-рецептора и эффекторной функцией
EA012617B1 (ru) * 2005-03-24 2009-10-30 ДСМ АйПи АССЕТС Б.В. Способ микробиального производства ценного соединения
WO2011039634A2 (en) * 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
JPS5754588A (en) 1980-09-19 1982-04-01 Eiji Ichijima Alpha-mannosidase
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5834251A (en) 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
WO1997044470A1 (en) 1996-05-21 1997-11-27 Novo Nordisk A/S Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2258307C (en) 1996-07-05 2008-02-12 Novo Nordisk A/S Method of producing heterologous short chain polypeptides by yeast with impaired yap3 protease
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
PT975775E (pt) 1997-04-23 2004-07-30 Vlaams Interuniv Inst Biotech Sistema regulador para a expressao induzivel de genes com promotores lambdoides
US7442772B2 (en) 1997-12-03 2008-10-28 Genentech, Inc. Antibodies to PRO361 polypeptide
WO1999037758A2 (en) 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
WO2001042462A2 (en) 1999-12-08 2001-06-14 National University Of Singapore Phospholipase a2 inhibitory peptides from python reticulatus
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
EP1283265B1 (en) 2000-05-17 2009-08-05 Mitsubishi Tanabe Pharma Corporation Process for producing protein with reduction of mannose phosphate in the sugar chain and glycoprotein produced thereby
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1294910B1 (en) 2000-06-30 2008-11-19 VIB vzw Protein glycosylation modification in pichia pastoris
ES2258371B1 (es) 2000-08-31 2007-05-16 Dong Kook Pharmaceutical Co. Ltd. Levadura transformante productora de hormona paratiroidea humana y procedimiento para producir la hormona.
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4774496B2 (ja) 2001-06-14 2011-09-14 独立行政法人産業技術総合研究所 α−マンノシダーゼ
JP4742191B2 (ja) 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
US7972809B2 (en) 2002-04-26 2011-07-05 National Institute Of Advanced Industrial Science & Technology Methylotrophic yeast producing mammalian type sugar chain
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
EP1534835B1 (en) 2002-06-29 2010-09-08 Korea Research Institute of Bioscience and Biotechnology Hansenula polymorpha yapsin deficient mutant strain and process for the preparation of recombinant proteins using the same
KR100470978B1 (ko) 2003-01-02 2005-03-10 한국생명공학연구원 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법
AU2012206984B2 (en) 2003-02-11 2015-07-09 Takeda Pharmaceutical Company Limited Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE)
JP4259169B2 (ja) 2003-04-16 2009-04-30 昭和産業株式会社 新規α−１，２−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法
US7259255B2 (en) 2003-06-25 2007-08-21 E. I. Du Pont De Nemours And Company Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast
CA2551484C (en) 2003-12-24 2015-03-31 Glycofi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
CN101084233B (zh) 2004-04-29 2012-08-15 格利科菲公司 用于在糖蛋白产生中减少或消除α-甘露糖苷酶抗性聚糖的方法
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP1910514A4 (en) 2005-04-14 2010-03-03 Oxyrane Uk Ltd RECOMBINANT HEEDS FOR SYNTHETIZING EPOXY HYDROLASES
EP1934605B1 (en) 2005-09-22 2014-03-26 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
JP2010517577A (ja) 2007-02-09 2010-05-27 メディミューン，エルエルシー 酵母細胞原形質膜による抗体ライブラリー提示
CA2887752C (en) 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
WO2008143354A1 (ja) 2007-05-18 2008-11-27 Tokyo Metropolitan Organization For Medical Research 酵素補充療法用医薬組成物
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US20100311122A1 (en) 2008-02-20 2010-12-09 Glycofi, Inc Vectors and yeast strains for protein production
JP5627571B2 (ja) * 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
WO2010099195A1 (en) 2009-02-26 2010-09-02 Glaxosmithkline Llc. Host cells and methods of use
WO2011061629A2 (en) 2009-11-19 2011-05-26 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
JP2013517761A (ja) 2010-01-21 2013-05-20 オキシレイン ユーケー リミテッド 酵母細胞の表面上にポリペプチドをディスプレイするための方法および組成物
US20120135461A1 (en) 2010-07-30 2012-05-31 William James Cook Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase
CA2812872C (en) 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
US20150031081A1 (en) 2011-12-30 2015-01-29 Oxyrane Uk Limited Methods and materials for reducing degradation of recombinant proteins
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005123986A (ru) * 2003-01-22 2007-02-27 Гликарт Биотекнолоджи АГ (CH) Конструкции слияния и их применение для получения антител с повышенными аффинностью связывания fc-рецептора и эффекторной функцией
EA012617B1 (ru) * 2005-03-24 2009-10-30 ДСМ АйПи АССЕТС Б.В. Способ микробиального производства ценного соединения
WO2011039634A2 (en) * 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIJVOET A. G. A. et al., Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, Vol.7, NO.11, pp.1815-1824, 1998. *
HIROKI TATSUMI et al., Cloning and Sequencing of the Alkaline Protease cDNA from Aspergillus oryzae, Vol.52, Issue 7, pp.1887-1888, 1988. *
JOHAN L. K. VAN HOVE et al., High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proceedings of the National Academy of Sciences, Vol.93, NO.1, pp.65-70, 1996. *
MORELAND R. J. et al., Lysosomal Acid alpha-Glucosidase Consists of Four Different Peptides Processed from a Single Chain Precursor, The Journal of Biological Chemistry, Vol.280, No.8, pp.6780-6791, 2005. *
ZHU Y. et al., Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease, Molecular Therapy, Vol.17, NO.6, pp.954-963, 2009. *
ZHU Y. et al., Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease, Molecular Therapy, Vol.17, NO.6, pp.954-963, 2009. BIJVOET A. G. A. et al., Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, Vol.7, NO.11, pp.1815-1824, 1998. JOHAN L. K. VAN HOVE et al., High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proceedings of the National Academy of Sciences, Vol.93, NO.1, pp.65-70, 1996. *

Also Published As

Publication number Publication date
JP2015516148A (ja) 2015-06-11
AU2013234042A1 (en) 2014-10-23
EP3628326B1 (en) 2024-02-28
JP6194324B2 (ja) 2017-09-06
RU2014139953A (ru) 2016-05-20
US20130243746A1 (en) 2013-09-19
EP2825193A2 (en) 2015-01-21
US9249399B2 (en) 2016-02-02
CN104379162A (zh) 2015-02-25
CA2867237A1 (en) 2013-09-19
EP3628326C0 (en) 2024-02-28
CN104379162B (zh) 2017-03-15
KR20190114003A (ko) 2019-10-08
EP3628326A1 (en) 2020-04-01
EP2825193B1 (en) 2019-11-13
BR112014022624A2 (pt) 2017-07-11
HK1200348A1 (en) 2015-08-07
KR20140135802A (ko) 2014-11-26
KR102028228B1 (ko) 2019-10-04
WO2013136189A2 (en) 2013-09-19
US10648044B2 (en) 2020-05-12
WO2013136189A3 (en) 2014-02-20
US20160279254A1 (en) 2016-09-29
CA2867237C (en) 2024-01-02
AU2013234042B2 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
RU2644258C2 (ru) Способы и материалы для лечения болезни помпе
US10392609B2 (en) Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
KR101983572B1 (ko) 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법
US20220204952A1 (en) Production of catalytically active type i sulfatase
EP3393501B1 (en) Human alpha-n-acetylgalactosaminidase polypeptide
HK1200348B (en) Methods and materials for treatment of pompe's disease
HK1171248A (en) Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose